Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.

Abstract: Provided are methods of treating, mitigating, or preventing or delaying the growth, proliferation, recurrence or metastasis of, a Trop-2 expressing cancer in a subject by administering an effective amount of: (a) an agent that inhibits binding between CD47 and SIRP? (e.g., magrolimab); and (b) an anti-Trop-2 antibody drug conjugate (ADC) (e.g., sacituzumab govitecan) to the subject.

Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.

Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.

Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.

Abstract: The present inventors have developed antigen-binding reagents and antigen-binding conjugates that recognize a cancer-specific glycan (carbohydrate) modification on the human Periostin protein. Various in vitro and in vivo diagnostic and/or therapeutic methods using these compositions are also disclosed herein specifically for treating cancers that have amplification of the Mgat3 gene.

Abstract: Disclosed are compositions comprising a mesothelin protein and an adjuvant. Disclosed are compositions comprising a mesothelin protein, an adjuvant, and a second adjuvant. In some instances the adjuvant is cyclic dinucleotides (CDNs). Disclosed are compositions comprising a mesothelin protein, CDNs, and a squalene based oil-in-water emulsion. Disclosed are methods of treating cancer comprising administering to a subject a composition or vaccine, wherein the composition or vaccine comprises a mesothelin protein, an adjuvant, and a second adjuvant.

Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.

Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.

Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.

Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.

Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: The present disclosure provides isolated nanobodies based on camelid VHH domains that specifically bind to mesothelin with high affinity. Also disclosed are conjugate constructs comprising the isolated nanobodies derivatized to allow conjugation to or that are conjugated to accessory moieties, such as biologically active moieties (e.g., a cytotoxin, a non-cytotoxic drug, a radioactive agent, a protein, or an enzyme) or detectable markers (e.g., a fluorescent label or biotin). Nucleic acid molecules encoding the nanobodies and conjugate constructs, expression vectors, host cells and methods for expressing the nanobodies and conjugate constructs are also provided. Pharmaceutical compositions comprising the nanobodies and conjugate-constructs as described herein are also provided. The present invention is also directed to methods for detecting mesothelin, as well as methods for diagnosis, treating, preventing and ameliorating mesothelin-associated diseases and conditions (e.g.

Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.

Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: Embodiments in accordance with the present disclosure include antibody binding domains that specifically bind to mesothelin. A nanobody or conjugate construct thereof can comprise the antibody binding domain comprising complementary determining region (CDR)1 of SEQ ID NO:05 or SEQ ID NO:08, CDR2 of SEQ ID NO:06 or SEQ ID NO:09, and/or CDR3 of SEQ ID NO:07 or SEQ ID NO:10. The nanobody or conjugate constructs of the nanobody can be used for diagnosis or treatment of diseases or conditions associated with overexpression of mesothelin.

Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.

Abstract: The invention relates to Anti-TEM 1 anti-bodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.